US4352799A - 2-Phenyl-1,2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases - Google Patents

2-Phenyl-1,2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases Download PDF

Info

Publication number
US4352799A
US4352799A US06/281,876 US28187681A US4352799A US 4352799 A US4352799 A US 4352799A US 28187681 A US28187681 A US 28187681A US 4352799 A US4352799 A US 4352799A
Authority
US
United States
Prior art keywords
phenyl
benzisoselenazol
pharmaceutical preparations
test
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/281,876
Inventor
Marcel Renson
Eugen Etschenberg
Johannes Winkelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Assigned to A. NATTERMANN & CIE GMBH reassignment A. NATTERMANN & CIE GMBH ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ETSCHENBERG, EUGEN, RENSON, MARCEL, WINKELMANN, JOHANNES
Application granted granted Critical
Publication of US4352799A publication Critical patent/US4352799A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention is related to pharmaceutical preparations for use in human or veterinary medicine containing the known compound 2-phenyl-1.2-benzisoselenazol-3(2H)-one as active component.
  • the pharmaceutical preparations according to the present invention may be used for the treatment of many diseases, for instance in the prophylaxis and therapy of infectious diseases, for the therapy of malign tumors, for the stimulation of the immunosystem or in the treatment of diseases caused by selen deficiencies as defined by W. KRAUSS and P. OEHME, Das Guide Railscher 1979, vol. 34 (3), pgs. 1713 to 1718 and 1979, vol. 34 (37), pgs. 1769 to 1773.
  • the new pharmaceutical preparations however are characterized by their anti-arteriosclerotic and anti-inflammatory properties. They are in particular useful in the treatment of rheumatic diseases such as arthrosis or chronical polyarthritis.
  • the new pharmaceutical preparations are particularly well compatible since its active agent has a low toxicity and, contrary to known anti-inflammatory agents, does not cause formation of ulcera or gastrointestinal irritations.
  • the antiphlogistic properties are determined in the rat pad edema test according to HILLEBRECHT (J. HILLEBRECHT, Arzneim. Forsch. 1954, vol. 4, p. 607).
  • HILLEBRECHT J. HILLEBRECHT, Arzneim. Forsch. 1954, vol. 4, p. 607.
  • the formation of an edema is caused in one of the hindpads of rats weighing each 200 to 250 grams, by subplantar injection of Carragenine (0.5% in 0.9% NaCl solution) in an amount of 0.1 ml. solution per each pad.
  • Carragenine (0.5% in 0.9% NaCl solution
  • the volume of the pad is determined in an overflow. 3 hours after administration of the test compound the final volume is determined.
  • test is carried out with 10 test animals and 10 control animals of one sex per each dose and is repeated with the same number of animals of the other sex.
  • percent inhibition of edema formation is determined over the control group. The following test values have been determined:
  • the active compound 2-phenyl-1.2-benzisoselenazol-3(2H)-one is known as such (see for instance Ber. 57 (1924) p. 1080) and may be produced by processes known as such (R. WEBER and M. RENSON, Bulletin de la Soc. Chim. de France 1976 (7/8), pgs. 1124 to 1126) by subjecting 2-methylseleno-N-phenyl-benzamid to reaction with phosphorus pentachloride ,nd subjecting the resulting product to hydrolysis.
  • this active component may be used as such or in combination with usual pharmaceutical carrier materials and may be formulated as usual.
  • the active compound may be applied in any known form as long as the formation and maintenance of a sufficient blood or tissue level is obtained thereby. Thus, this is possible after oral or rectal or parenteral administration of a suitable dose.
  • Pharmaceutical preparations for single dosage administrations are preferred such as tablets, dragees, capsules, suppositories, granulates, solutions, emulsions, suspensions, soles or gels.
  • the dose in general is between 10 and 1,000 mg. per day, preferably between 30 and 300 mg. per day and may be administered in a single or in several dosages, preferably in two or three dosages per day.
  • Suitable carrier materials which may be used for pharmaceutical preparations to be administered orally such as tablets, capsules, granulates or powders, are calcium carbonate, calcium phosphate, starch, sugar, lactose, talcum, magnesium stearate, gelatine, polyvinylpyrrolidone, gum arabic, sorbitol, microcristalline cellulose, polyethyleneglycol, carboxymethyl cellulose, shellac or the like. Tablets may be coated in usual manners.
  • Liquid pharmaceutical preparations for oral administrations may be aqueous or oily suspensions or solutions, sirups or the like. They are produced in usual manners.
  • Injectable preparations may be aqueous or oily suspensions or solutions, powderous products containing a filler or lyophilised products which are dissolved before administration. These products are also produced in known manners.
  • the pharmaceutical products according to the present invention may also be suppositories for rectal administration which may contain pharmaceutically acceptable carrier materials as they are known for this purpose, for instance polyethylene glycol, lanoline, coconut butter, Witepsol® or the like.
  • pharmaceutically acceptable carrier materials for instance polyethylene glycol, lanoline, coconut butter, Witepsol® or the like.
  • External pharmaceutical preparations are preferably produced as ointments or cremes in usual manners using usual components.
  • the above components are mixed and pressed to tablets in a usual manner using usual equipment. If desired, the tablets may be coated with a usual coating.
  • the above components are mixed and granulated as usual and filled into hard gelatine capsules.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is related to pharmaceutical preparations containing as active components the known compound 2-phenyl-1.2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment in particular of rheumatic diseases.

Description

The present invention is related to pharmaceutical preparations for use in human or veterinary medicine containing the known compound 2-phenyl-1.2-benzisoselenazol-3(2H)-one as active component.
The pharmaceutical preparations according to the present invention may be used for the treatment of many diseases, for instance in the prophylaxis and therapy of infectious diseases, for the therapy of malign tumors, for the stimulation of the immunosystem or in the treatment of diseases caused by selen deficiencies as defined by W. KRAUSS and P. OEHME, Das Deutsche Gesundheitswesen 1979, vol. 34 (3), pgs. 1713 to 1718 and 1979, vol. 34 (37), pgs. 1769 to 1773.
The new pharmaceutical preparations however are characterized by their anti-arteriosclerotic and anti-inflammatory properties. They are in particular useful in the treatment of rheumatic diseases such as arthrosis or chronical polyarthritis. The new pharmaceutical preparations are particularly well compatible since its active agent has a low toxicity and, contrary to known anti-inflammatory agents, does not cause formation of ulcera or gastrointestinal irritations.
The excellent anti-inflammatory properties and the high compatibility of the new pharmaceutical preparations has been determined for instance in the following test methods:
1. The rat pad edema test
The antiphlogistic properties are determined in the rat pad edema test according to HILLEBRECHT (J. HILLEBRECHT, Arzneim. Forsch. 1954, vol. 4, p. 607). In this test, the formation of an edema is caused in one of the hindpads of rats weighing each 200 to 250 grams, by subplantar injection of Carragenine (0.5% in 0.9% NaCl solution) in an amount of 0.1 ml. solution per each pad. After administration of the test compound in an amount which in general should not be larger than a volume of 10 ml. per kg. body weight, the volume of the pad is determined in an overflow. 3 hours after administration of the test compound the final volume is determined. The test is carried out with 10 test animals and 10 control animals of one sex per each dose and is repeated with the same number of animals of the other sex. For evaluation purposes the percent inhibition of edema formation is determined over the control group. The following test values have been determined:
              TABLE 1                                                     
______________________________________                                    
Edema inhibition in rats                                                  
           2-Phenyl-1.2-benz-                                             
           isoseleneazol-3(2H)-one                                        
                          Indometacin                                     
______________________________________                                    
Dose (mg./kg. p.o.)                                                       
             0.1     1.0    10   3.8  5.6   8.3                           
Inhibitory effect (%)                                                     
             -1      -57    -40  -26  -45   -57                           
Dose (mg./kg. i.m.)                                                       
             0.1     1.0    10   1    3     10                            
Inhibitory effect (%)                                                     
             -23     -62    -35  -9   -23   -33                           
______________________________________
2. Granuloma test (cotton-pellet-test) according to R. MEIER et al., Experientia 6, 469 (1950)
In this test, cotton pellets impregnated with crotone oil are implanted subcutaneously into the test animals (rats) which impregnated cotton pellets cause the formation of granuloma in the connective tissue. After killing of the test animals, the granuloma are separated and recovered and are weighed as wet or dry tissue. The anti-proliferatic activity of an antiphlogistic agent is expressed in a lower granuloma weight in comparison to untreated control animals.
              TABLE 2                                                     
______________________________________                                    
Antiproliferatic activity                                                 
          2-Phenyl-1.2-benziso-                                           
          selenazol-3(2H)-one                                             
                       Indometacin                                        
______________________________________                                    
Dose (mg./kg. p.o.)                                                       
            0.1     1       10   1     3.2  5.6                           
Decrease of granu-                                                        
loma weight (%)                                                           
            -22     -21     -20  -21   -7   -6                            
______________________________________
3. Adjunct-Arthritis (C. M. PEARSON, Proc.Soc.exp.Biol. 91, 95-101 (1956)
There are used 10 wistar rats each weighing 120 to 150 g. per each dose. The same number of animals is used as control group. An arthritis is caused by subplantar injection of 0.5 ml. of Freud adjuvans. The test duration is 17 days. At the beginning of the test the volume of the pads of all for legs is determined as starting value. The volume is further determined on the 8th, 14th and 17th day of the test. In the evaluation, the difference between the pad volume at the beginning and at the end of the test is determined both in the test group as well as in the control group. The test result, i.e. the inhibition of the growth of the pad volume is expressed in percent.
              TABLE 3                                                     
______________________________________                                    
Adjunct-Arthritis in rats, p.o.                                           
          2-Phenyl-1,2-                                                   
          benzisoselenazol-                                               
          3(2H)-one    Indometacin                                        
______________________________________                                    
Dose (mg./kg. p.o.)                                                       
            0.1     1      10    0.1  1    10                             
inhibitory effect (%)                                                     
 7th day p.i.                                                             
            -22     -46    -30   -32  -50  lethal                         
14th day p.i.                                                             
            -10     -36    -22   -25  -40  lethal                         
17th day p.i.                                                             
            -13     -33    -24   -37  -40  lethal                         
______________________________________
The results in Table 3 show that 2-phenyl-1.2-benzisoselenazol-3(2H)-one is characterized by a substantially improved therapeutical range. Even at higher doses no toxicity effects occur.
4. Ulcus test
The determination of ulcus formation is carried out according to W. J. R. WHITTLE, Brit.J.Pharmacology 1975, vol. 55, pgs. 242 to 243; L. MARIANI, Europ. J. Toxicol. Eviron, 1975, vol. 8, pgs. 335 to 339; R. MENGUY and L. DESBAILLETS, Proc.Soc.Exp.Bio., vol. 125, p. 1108. In this test, 10 female and 10 male wistar rats are used each weighing 120 to 150 g. and which had been fed only with hydrocarbons for 2 days and were kept thereafter without feeding for 16 hours. The formation of a bleeding ulcus of the stomach was provocated by oral application of the compound to be tested. 3.5 hours after administration the test animals were killed, the stomach was separated, opened along the large curvature and fixed to a polystyrol plate. There is determined the number and size of average ulcus formation both in the test group and in the control group. All known antiphlogistics which can be used therapeutically and do not represent a steroid produce ulceration of the mucous membrane of the stomach under these conditions within the therapeutical dose range.
              TABLE 4                                                     
______________________________________                                    
Ulcus formation in rats                                                   
          2-Phenyl-1.2-                                                   
          benzoisoelenazol-                                               
          3(2H)-one  Indometacin                                          
______________________________________                                    
Dose (mg./kg. p.o.)                                                       
            1      10     100  3.2   5.6   7.5                            
effectiveness                                                             
            0       0      0   ++    +++   +++                            
______________________________________                                    
 0 = no ulcus formation                                                   
 + = moderate ulcus formation                                             
 ++ = considerable ulcus formation                                        
 +++ = very strong ulcus formation                                        

              TABLE 5                                                     
______________________________________                                    
Toxicity                                                                  
             2-Phenyl-1.2-                                                
             benzisoselenazol-                                            
             3(2H)-one  Indometacin                                       
______________________________________                                    
(a)   in rats, p.o.                                                       
      dose (mg./kg.)                                                      
                    4,600       38                                        
      lethality (%)                                                       
                   0            50                                        
(b)   in mice, p.o.                                                       
      dose (mg./Kg.)                                                      
                   >2,150       19                                        
      lethality (%)                                                       
                   0            50                                        
______________________________________
The active compound 2-phenyl-1.2-benzisoselenazol-3(2H)-one is known as such (see for instance Ber. 57 (1924) p. 1080) and may be produced by processes known as such (R. WEBER and M. RENSON, Bulletin de la Soc. Chim. de France 1976 (7/8), pgs. 1124 to 1126) by subjecting 2-methylseleno-N-phenyl-benzamid to reaction with phosphorus pentachloride ,nd subjecting the resulting product to hydrolysis.
For producing the new pharmaceutical preparations according to the present invention containing 2-phenyl-1.2-benzisoselenazol-3(2H)-one as active component, this active component may be used as such or in combination with usual pharmaceutical carrier materials and may be formulated as usual. For use in human or veterinary medicin, the active compound may be applied in any known form as long as the formation and maintenance of a sufficient blood or tissue level is obtained thereby. Thus, this is possible after oral or rectal or parenteral administration of a suitable dose. Pharmaceutical preparations for single dosage administrations are preferred such as tablets, dragees, capsules, suppositories, granulates, solutions, emulsions, suspensions, soles or gels. The dose in general is between 10 and 1,000 mg. per day, preferably between 30 and 300 mg. per day and may be administered in a single or in several dosages, preferably in two or three dosages per day.
Suitable carrier materials which may be used for pharmaceutical preparations to be administered orally such as tablets, capsules, granulates or powders, are calcium carbonate, calcium phosphate, starch, sugar, lactose, talcum, magnesium stearate, gelatine, polyvinylpyrrolidone, gum arabic, sorbitol, microcristalline cellulose, polyethyleneglycol, carboxymethyl cellulose, shellac or the like. Tablets may be coated in usual manners. Liquid pharmaceutical preparations for oral administrations may be aqueous or oily suspensions or solutions, sirups or the like. They are produced in usual manners. Injectable preparations may be aqueous or oily suspensions or solutions, powderous products containing a filler or lyophilised products which are dissolved before administration. These products are also produced in known manners.
The pharmaceutical products according to the present invention may also be suppositories for rectal administration which may contain pharmaceutically acceptable carrier materials as they are known for this purpose, for instance polyethylene glycol, lanoline, coconut butter, Witepsol® or the like. External pharmaceutical preparations are preferably produced as ointments or cremes in usual manners using usual components.
EXAMPLE 1 
______________________________________                                    
Tablets                                                                   
______________________________________                                    
2-phenyl-1.2-benzisoselenazol-3(2H)-one                                   
                          30 mg.                                          
lactose                   150 mg.                                         
cristalline cellulose     50 mg.                                          
calciumcarboxymethyl cellulose                                            
                          7 mg.                                           
magnesium stearate        3 mg.                                           
______________________________________
The above components are mixed and pressed to tablets in a usual manner using usual equipment. If desired, the tablets may be coated with a usual coating.
EXAMPLE 2 
______________________________________                                    
Tablets                                                                   
______________________________________                                    
2-phenyl-1.2-benzisoselenazol-3(2H)-one                                   
                          50 mg.                                          
microcristalline cellulose                                                
                          150 mg.                                         
Cutina HR                 15 mg.                                          
hydroxypropylmethyl cellulose phthalat                                    
                          20 mg.                                          
______________________________________
EXAMPLE 3 
______________________________________                                    
Capsules                                                                  
______________________________________                                    
2-phenyl-1.2-benzisoselenazol-3(2H)-one                                   
                          30 mg.                                          
lactose                   102 mg.                                         
cristalline cellulose     56 mg.                                          
kolloidal silica          2 mg.                                           
______________________________________
The above components are mixed and granulated as usual and filled into hard gelatine capsules.
EXAMPLE 4 
______________________________________                                    
Capsules                                                                  
______________________________________                                    
2-phenyl-1.2-benzisoselenazol-3(2H)-one                                   
                          50 mg.                                          
talcum                    5 mg.                                           
aerosil 200               10 mg.                                          
______________________________________
are mixed, granulated and filled into hard gelatine capsules.

Claims (1)

What we claim is:
1. A process for the treatment of rheumatic diseases comprising administering to a being suffering from such disease 2-phenyl-1.2-benzisoselenazol-3(2H)-one and, optionally, a carrier material therewith, in an amount ranging from 10 to 1000 mg per day.
US06/281,876 1980-07-17 1981-07-09 2-Phenyl-1,2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases Expired - Lifetime US4352799A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3027073A DE3027073C2 (en) 1980-07-17 1980-07-17 Pharmaceutical preparations containing 2-phenyl-1,2-benzisoselenazol-3 (2H) -one
DE3027073 1980-07-17

Publications (1)

Publication Number Publication Date
US4352799A true US4352799A (en) 1982-10-05

Family

ID=6107415

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/281,876 Expired - Lifetime US4352799A (en) 1980-07-17 1981-07-09 2-Phenyl-1,2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases

Country Status (9)

Country Link
US (1) US4352799A (en)
EP (1) EP0044971B1 (en)
JP (1) JPS5756427A (en)
AT (1) ATE4168T1 (en)
CA (1) CA1177409A (en)
DE (1) DE3027073C2 (en)
DK (1) DK319481A (en)
IE (1) IE51996B1 (en)
ZA (1) ZA814607B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618669A (en) * 1984-06-22 1986-10-21 A. Nattermann & Cie Gmbh S-(carbamoyl-phenylselenyl) derivatives of glutathione and of aminomercaptocarboxylic acids
US4711961A (en) * 1984-03-01 1987-12-08 A. Nattermann & Cie Gmbh Benzisoselenazolethiones and process for the treatment of various diseases in humans
US4730053A (en) * 1984-11-29 1988-03-08 A. Nattermann & Cie Gmbh S-[2-phenyl (alkyl) carbamoyl]-phenylselenylmercapto derivatives
US4757063A (en) * 1986-05-20 1988-07-12 A. Nattermann & Cie. Gmbh Process for the treatment of diseases caused by oxidative stress
US4774252A (en) * 1985-04-27 1988-09-27 A. Nattermann & Cie Gmbh Benzisoselenazolonyl derivatives and processes for the treatment of rheumatic disease
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
US4784994A (en) * 1986-06-20 1988-11-15 A. Nattermann & Cie Gmbh Process for the treatment of inflammatory and allergic diseases
US4873350A (en) * 1985-04-12 1989-10-10 A Nattermann & Cie Gmbh Diselenobis-benzoic acid amides of primary and secondary amines and processes for the treatment of diseases in humans caused by a cell injury
US4910313A (en) * 1986-08-06 1990-03-20 Nattermann & Cie Gmbh Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and process for the treatment of certain diseases in humans
US5021242A (en) * 1987-06-20 1991-06-04 A. Nattermann & Cie Gmbh Solid drug preparations containing micronized crystals of ebselen
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
US6335036B1 (en) * 1993-10-27 2002-01-01 Daiichi Pharmaceutical Co., Ltd. Granular pharmaceutical preparation of ebselen
US20030157191A1 (en) * 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
US20050113427A1 (en) * 2001-10-12 2005-05-26 Arginox, Inc. Use of peroxynirite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
US20060211745A1 (en) * 2005-03-08 2006-09-21 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US7671211B1 (en) 1999-03-31 2010-03-02 Arne Holmgren Substrates for thioredoxin reductase
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US11464784B2 (en) * 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226286A1 (en) * 1982-07-14 1984-01-19 A. Nattermann & Cie GmbH, 5000 Köln CYCLOALKYL DERIVATIVES OF BENZISOSELENAZOLONES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3226284A1 (en) * 1982-07-14 1984-01-19 A. Nattermann & Cie GmbH, 5000 Köln NEW BENZISOSELENAZOLONES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3638124C2 (en) * 1986-11-08 1996-09-05 Nattermann A & Cie New pharmaceutical use of Ebselen
DE3827093A1 (en) * 1988-08-10 1990-02-15 Nattermann A & Cie METHOD FOR THE PRODUCTION OF HIGH PURE PLEASURE
DE3836892A1 (en) * 1988-10-29 1990-05-03 Nattermann A & Cie PARENTERAL APPLICABLE, STABLE MEDICINAL SOLUTIONS
DE4024885C2 (en) * 1990-08-06 2002-07-18 Nattermann A & Cie Use of 2-phenyl-1,2-benzisoselenazol-3 (2H) -one
JP2553434B2 (en) * 1992-04-28 1996-11-13 第一製薬株式会社 Granular formulation
AU5513796A (en) * 1995-04-25 1996-11-18 Daiichi Pharmaceutical Co., Ltd. Remedy for acquired immunodeficiency syndrome
JP2000016935A (en) * 1998-07-01 2000-01-18 Dai Ichi Seiyaku Co Ltd Cyclooxygenase inhibitor

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711961A (en) * 1984-03-01 1987-12-08 A. Nattermann & Cie Gmbh Benzisoselenazolethiones and process for the treatment of various diseases in humans
US4618669A (en) * 1984-06-22 1986-10-21 A. Nattermann & Cie Gmbh S-(carbamoyl-phenylselenyl) derivatives of glutathione and of aminomercaptocarboxylic acids
US4730053A (en) * 1984-11-29 1988-03-08 A. Nattermann & Cie Gmbh S-[2-phenyl (alkyl) carbamoyl]-phenylselenylmercapto derivatives
US4873350A (en) * 1985-04-12 1989-10-10 A Nattermann & Cie Gmbh Diselenobis-benzoic acid amides of primary and secondary amines and processes for the treatment of diseases in humans caused by a cell injury
US4774252A (en) * 1985-04-27 1988-09-27 A. Nattermann & Cie Gmbh Benzisoselenazolonyl derivatives and processes for the treatment of rheumatic disease
US4757063A (en) * 1986-05-20 1988-07-12 A. Nattermann & Cie. Gmbh Process for the treatment of diseases caused by oxidative stress
US4784994A (en) * 1986-06-20 1988-11-15 A. Nattermann & Cie Gmbh Process for the treatment of inflammatory and allergic diseases
US4910313A (en) * 1986-08-06 1990-03-20 Nattermann & Cie Gmbh Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and process for the treatment of certain diseases in humans
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
US5021242A (en) * 1987-06-20 1991-06-04 A. Nattermann & Cie Gmbh Solid drug preparations containing micronized crystals of ebselen
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
US6335036B1 (en) * 1993-10-27 2002-01-01 Daiichi Pharmaceutical Co., Ltd. Granular pharmaceutical preparation of ebselen
US7671211B1 (en) 1999-03-31 2010-03-02 Arne Holmgren Substrates for thioredoxin reductase
US20050113427A1 (en) * 2001-10-12 2005-05-26 Arginox, Inc. Use of peroxynirite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
US20060089313A1 (en) * 2001-11-29 2006-04-27 Sound Pharmaceuticals Inc. Methods and compositions for ameliorating the undesirable effects of chemotherapy
US20030157191A1 (en) * 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US20110065729A1 (en) * 2001-11-29 2011-03-17 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US8309560B2 (en) 2001-11-29 2012-11-13 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
US7820640B2 (en) 2002-01-04 2010-10-26 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
US20060211745A1 (en) * 2005-03-08 2006-09-21 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US20110020470A1 (en) * 2005-03-08 2011-01-27 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US11013730B1 (en) 2014-09-12 2021-05-25 Thioredoxin Systems Ab Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith
US11464784B2 (en) * 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer

Also Published As

Publication number Publication date
ZA814607B (en) 1982-07-28
DE3027073A1 (en) 1982-02-18
IE51996B1 (en) 1987-05-13
DE3027073C2 (en) 1985-03-07
JPH026331B2 (en) 1990-02-08
DK319481A (en) 1982-01-18
CA1177409A (en) 1984-11-06
JPS5756427A (en) 1982-04-05
EP0044971A1 (en) 1982-02-03
EP0044971B1 (en) 1983-07-20
ATE4168T1 (en) 1983-08-15
IE811514L (en) 1982-01-17

Similar Documents

Publication Publication Date Title
US4352799A (en) 2-Phenyl-1,2-benzisoselenazol-3(2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases
US5401777A (en) Use of preparations of curcuma plants
AU705692B2 (en) Preparation containing a combination of 5-methylisoxazole-4 -carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
EP0034214B1 (en) Use of rosmarinic acid in the treatment of inflammations and pharmaceutical products used therein
DE3720493A1 (en) MEDICINAL PREPARATIONS WITH MICRONIZED EBSELEN CRYSTALS
IE62333B1 (en) Use of aromatic carboxylic acid amides
US4397858A (en) Treatment of rheumatism and arteriosclerosis with n-halogenophenyl-benzisothiazoles
US4328246A (en) Anti Walker 256 carcinoma agent and combination thereof
US2567814A (en) Tetraethyl thiuram disulfide alcoholism treatment composition
US3870792A (en) Certain dihydrophthalizines for treating hemorrhage and thrombosis
US2507468A (en) Monobasic phosphate of 1-phenyl-2-aminopropane
US4447437A (en) Pharmaceutical composition and method for treatment of peptic ulcer
US3781434A (en) Methods of producing antiarthritic activity using 3-substituted phenyl-2-thio-1,3-thiazane-2,4-dione
US4096247A (en) Gold thio glucopyranoside compounds and method of use
US3482021A (en) Anti-phlogistic and analgesic compositions and methods for relieving inflammatory conditions
AU613734B2 (en) Method for treating hyperuricemia
US3773958A (en) Methods of producing anti-arthritic activity using 3-substituted-thio-2,4-thiazolidinedione
US3658964A (en) 2-phenylacetylbenzoic acid in the treatment of inflammation
US3840662A (en) Method of treating atherosclerosis using 4-hydroxymethyl-1-keto-1,2-dihydrophthalazine or acid salts thereof
EP0369088B1 (en) Use of zinc acexamate in the prophylaxis of gastropathy induced by non-steroidal anti-inflammatory drugs
US3264183A (en) Process for effecting diuresis
US4093719A (en) Antiarthritic compositions comprising bis[(trialkyl-phosphine)gold(I)]sulfides and methods of producing antiarthritic activity
US3845213A (en) 1,2-diphenyl-3,5-dioxopyrazolidine compounds used to treat inflammation
AU607908B2 (en) Pharmaceutical compositions for use in improving oxygenation of the brain and a process for their production
US3181993A (en) Water-soluble salicylic acid derivatives as analgesics and antipyretics

Legal Events

Date Code Title Description
AS Assignment

Owner name: A. NATTERMANN & CIE GMBH; NATTERMANNALLEE 1, 5000

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:RENSON, MARCEL;ETSCHENBERG, EUGEN;WINKELMANN, JOHANNES;REEL/FRAME:003933/0995

Effective date: 19811122

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M185); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12